Arecor Therapeutics
plc
("Arecor"
or the "Group")
ARECOR TO HOST COMPANY AND
KOL WEBINAR TODAY TO DISCUSS CLINICAL TRIAL RESULTS FOR
ULTRA-CONCENTRATED ULTRA-RAPID ACTING INSULIN AT278 DEMONSTRATING
SUPERIORITY IN PEOPLE WITH TYPE 2 DIABETES
·
Company will host a CEO and key opinion leader webinar at
14.30 BST
·
AT278
demonstrates significantly accelerated PK/PD profile compared to
NovoRapid® and Humulin® R U-500 in people with Type 2 Diabetes and
high BMI
·
Confirms previous trial results in people with Type 1
diabetes, demonstrating AT278 can maintain fast and superior onset
of action and glucose lowering profile irrespective of diabetes
type and BMI
·
Enables delivery of a highly concentrated, low volume
injection, offering more effective mealtime glucose control to meet
growing unmet need in patients requiring high daily doses of
insulin
·
Creates potential to be the first, and only,
ultra-concentrated (500 U/mL) ultra-rapid insulin product enabling
miniaturisation of next-generation insulin pumps
Cambridge, UK, 21 May 2024: Arecor Therapeutics plc (AIM:
AREC), the biopharmaceutical group
advancing today's therapies to enable healthier lives,
today announces that it will host a CEO and key
opinion leader webinar on the results of its Phase I clinical trial
of that its ultra-concentrated, ultra-rapid acting insulin
candidate, AT278. As announced on
20 May 2024, AT278 et all primary and secondary endpoints, and
also demonstrated superiority to NovoRapid® and Humulin® R U-500,
in a Phase I clinical trial in Type 2 diabetics with a high body
mass index (BMI).
AT278 (500 U/mL) is an ultra-concentrated,
ultra-rapid acting, novel formulation of insulin that accelerates
the absorption of insulin post injection, even when delivered at a
high concentration, and hence a lower injection volume. With no
concentrated (>200 U/mL), rapid acting insulins on the market,
AT278 has potential to be the first, and only, insulin available to
the growing number of patients with high daily insulin
requirements.
Speakers at the webinar will be:
·
Professor Thomas Pieber, Principal
Investigator for the ARE-278-104 clinical trial and Professor of
Medicine, Head of the Division of Endocrinology and Metabolism and
Chairman of the Department of Internal Medicine at Medical
University of Graz, Austria
·
Sarah Howell, Chief Executive
Officer of Arecor
To register to join the live webcast
click here and
to register for the conference line to ask questions
click here.
Please contact ICR Consilium for
details on arecor@consilium-comms.com.
-ENDS-
For more
information, please contact:
Arecor
Therapeutics plc
|
www.arecor.com
|
Dr Sarah
Howell, Chief Executive Officer
|
Tel: +44 (0)
1223 426060
Email:
info@arecor.com
|
|
|
Panmure Gordon
(UK) Limited (NOMAD and Broker)
Freddy Crossley, Emma Earl (Corporate
Finance)
Rupert Dearden (Corporate Broking)
|
Tel: +44 (0)
20 7886 2500
|
|
|
WG Partners
LLP (Financial
Advisor)
Nigel Barnes, Satheesh Nadarajah
David Wilson, Claes
Spang
|
Tel: +44
(0)203 705 9321
|
|
|
ICR
Consilium
|
|
Chris Gardner, David Daley, Lindsey
Neville
|
Tel: +44 (0) 20 3709 5700
Email:
arecor@consilium-comms.com
|
Notes to
Editors
About
Arecor
Arecor Therapeutics plc is a globally focused
biopharmaceutical company transforming patient care by bringing
innovative medicines to market through the enhancement of existing
therapeutic products. By applying our innovative proprietary
technology platform, Arestat™, we are developing an internal
portfolio of proprietary products in diabetes and other
indications, as well as working with leading pharmaceutical and
biotechnology companies to deliver therapeutic products. The
Arestat™ platform is supported by an extensive patent
portfolio.
For further
details please see our website, www.arecor.com